Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.

@article{Jung2012CalciumBD,
  title={Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.},
  author={Hyun Jung and Zheng Chen and Michael Wang and Luis E. Fayad and Jorge E Romaguera and Larry W. Kwak and Nami McCarty},
  journal={Blood},
  year={2012},
  volume={119 11},
  pages={
          2568-78
        }
}
Although bortezomib is clinically approved for the treatment of mantle cell lymphoma (MCL), only limited effects of this treatment have been demonstrated. To improve survival for bortezomib-resistant patients, it is necessary to develop new therapeutic strategies. In the present study, we used biochemical and molecular methodologies to demonstrate that tissue transglutaminase (TG) activates downstream NF-κB signaling pathways. The signaling axis from TG to NF-κB could be a new therapeutic… Expand
TG2 and NF-κB Signaling Coordinates the Survival of Mantle Cell Lymphoma Cells via IL6-Mediated Autophagy.
TLDR
An interconnected network of TG2/NF-κB and IL6/STAT3 signaling with autophagy regulation in MCL cells is uncovered, the disruption of which may offer a promising therapeutic strategy. Expand
Effect of Tissue Transglutaminase on Steroid Resistance in T-Cell Acute Lymphoblastic Leukemia
TLDR
Inhibition of TG2 suppressed steroid resistance and improved steroid cytotoxicity in steroid-adapted subclones of T-ALL in association with reduced NF-κB activity. Expand
The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma
TLDR
This review summarizes the discovery, mechanisms of -action and resistance, preclinical- clinical-developments, and FDA approval of BTZ for treatments of MCL. Expand
Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
TLDR
The molecular mechanisms associated with intrinsic and acquired resistance to BTZ learning from MM and MCL experience are recapitulate, including mutations of crucial genes and activation of prosurvival signalling pathways inherent to malignant B cells. Expand
NF-κB signaling and its relevance to the treatment of mantle cell lymphoma
TLDR
Targeted agents such as ibrutinib, an inhibitor of Bruton’s tyrosine kinase, which has been approved only in the relapsed setting, can be used to treat patients with relapsed or refractory mantle cell lymphoma. Expand
MTI-101 treatment inducing activation of Stim1 and TRPC1 expression is a determinant of response in multiple myeloma
TLDR
It is demonstrated that MTI-101 is synergistic when combined with bortezomib, using both myeloma cell lines and primary myel cancer patient specimens, suggesting that relapse may occur at a cost for increased sensitivity to Ca2+ overload mediated cell death. Expand
Profiling Bortezomib Resistance in Multiple Myeloma: Implications in Personalized Pharmacotherapy
TLDR
It is concluded that robust approaches using multiple data types are of primary importance in profiling drug resistance in MM to create a pharmacogenomic profiling-guided therapeutic response score that can be routinely applied in clinical settings to improve selective response to available drugs, predict effective combinations, and identify secondary therapies to circumvent the challenges in the relapsed patient. Expand
Resistance to Proteasome Inhibitors in Cancer
  • Q. Dou
  • Chemistry
  • Resistance to Targeted Anti-Cancer Therapeutics
  • 2014
Selective protein degradation by the ubiquitin–proteasome pathway (UPP) is critical to cellular homeostasis, and dysregulation of the UPP has been associated with human diseases including cancer.Expand
Tissue transglutaminase mediates the pro-malignant effects of oncostatin M receptor over-expression in cervical squamous cell carcinoma
TLDR
It is shown that tissue transglutaminase (TGM2) is an important mediator of the ligand‐dependent phenotypic effects of OSMR over‐expression in SCC cells, and an OSMR/TGM 2/integrin‐α5β1/fibronectin pathway is of biological significance in cervical SCC and a candidate for therapeutic targeting. Expand
Tissue Transglutaminase Constitutively Activates HIF-1α Promoter and Nuclear Factor-κB via a Non-Canonical Pathway
TLDR
This work shows for the first time a direct link between TG2, NF-κB, and HIF-1α, demonstrating TG2's important role in cancer progression and suggests that TG2 binds with IκBα and results in its rapid degradation via a non-proteasomal pathway. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 57 REFERENCES
Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma
TLDR
The findings show that bortezomib-resistant NF-κB activity is frequently observed in MCL samples and suggest that this activity may be relevant to MCL biology as well as serve as a potential therapeutic target. Expand
Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress
TLDR
A fraction of MM cells may acquire bortezomib resistance by suppressing apoptotic signals through the inhibition of unfolded protein accumulation and subsequent excessive ER stress by a mutation of the PSMB5 gene. Expand
Inhibition of Constitutive NF-κB Activation in Mantle Cell Lymphoma B Cells Leads to Induction of Cell Cycle Arrest and Apoptosis1
TLDR
It is suggested that constitutive NF-κB expression plays a key role in the growth and survival of MCL cells, and that PS-341 and BAY 11 may be useful therapeutic agents for MCL, a lymphoma that is refractory to most current chemotherapy regimens. Expand
Calcium Channel Blocker Verapamil Enhances Reticulum Stress and Death Induced by Proteasome Inhibition in Myeloma Cells
TLDR
It is concluded that verapamil increased the antimyeloma effect of bortezomib by enhancing ER stress signals along with NF-κB inhibition, leading to cell death, and may improve the efficacy of proteasome inhibitory therapy. Expand
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
TLDR
It is demonstrated that bortezomib significantly down-regulated IkappaBalpha expression and triggered NF-kappaB activation in MM cell lines and primary tumor cells from MM patients, suggesting that bortsomib-induced cytotoxicity cannot be fully attributed to inhibition of canonical NF- kappaB activity in MM cells. Expand
Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells.
TLDR
It is concluded that verapamil increased the antimyeloma effect of bortezomib by enhancing ER stress signals along with NF-kappaB inhibition, leading to cell death, and may improve the efficacy of proteasome inhibitory therapy. Expand
Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma.
TLDR
This article is the first to show that stem-like MCL cells utilize constitutive NF-κB expression for survival, and it will be important to find alternative therapeutic strategies to inhibit NF- KakB expression. Expand
Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma
TLDR
Bortezomib triggers an oxidative stress response in vitro and in vivo, and activation of this homeostatic program was significantly stronger in tumors with the best clinical response, suggesting high cellular antioxidant capacity contributes to bortzomib resistance. Expand
Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation.
TLDR
Examining several different breast cancer cell lines found that doxorubicin-resistant cells had a higher level of TGase 2 compared with dox orubicIn-sensitive cells independent of the EGFR expression level, and increased expression of TG enzyme 2 and subsequent activation of NF-kappaB may contribute to drug resistance in breast cancer cells independently of EGF signaling. Expand
Tissue transglutaminase-mediated chemoresistance in cancer cells.
  • A. Verma, K. Mehta
  • Biology, Medicine
  • Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  • 2007
TLDR
The inhibition of endogenous TG2 by small interfering RNA (siRNA) resulted in the reversal of drug resistance and the invasive phenotype, and ectopic expression of TG2 promoted cell survival, cell motility and invasive functions of cancer cells. Expand
...
1
2
3
4
5
...